Sanofi ($SNYNF) announced an update on their ongoing clinical study. Study Overview: Sanofi is conducting a Phase 2 clinical trial titled A ...

Sanofi ($SNYNF) announced an update on their ongoing clinical study. Sanofi’s recent clinical study, officially titled ‘A Phase 3, Randomized, ...

Rival European pharma giants Sanofi and GSK have both forged new partnerships to bolster their preclinical research. | Rival ...

Sanofi’s latest fair value estimate has been nudged down from €106.26 to €105.20 as analysts factor in slightly softer revenue growth assumptions, even as the company’s overall risk profile remains ...

Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseasesQfitlia, the first antithrombin-lowering therapy for hemophilia, ...

Sanofi is expanding options for those with hemophilia with its new treatment, Qfitlia (fitusiran). Approved this year, ...

Sanofi completes acquisition of VicebioParis, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”).

Sanofi (NASDAQ:SNY) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Sanofi (NASDAQ:SNY) has ...

Sanofi SA’s Paris headquarters were raided Tuesday by French authorities as part of a tax fraud investigation into a financing deal provided by Societe Generale SA.

In this morning's Pharmalittle roundup, we're reading about FDA scrutiny of RSV therapies, an AI tool for clinical trials, ...

Paris: French multinational pharmaceutical giant, Sanofi, has announced the completion of its acquisition of Vicebio Ltd.This ...

U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective RSV treatments for infants would face fresh safety scrutiny following ...